Business Wire

TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)

Share

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), today announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impact of HMTM on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration. Blood concentration of NfL showed a statistically significant 93% reduction in change over 12 months in participants receiving HMTM at a dose of 16 mg/day relative to the control group, which correlated significantly with a tau biomarker (p-tau 181) in blood.

Neurofilaments and tau proteins are essential for neuronal structure and function in the brain. In AD, tau protein aggregates to form toxic fibrils, which damage neurons. The extent of this damage can be measured by the amount of leakage of neurofilament protein into the bloodstream. NfL concentration in blood is known to correlate with tau pathology, disease severity, and therefore cognitive decline and brain atrophy in AD. HMTM, a tau aggregation inhibitor, was designed to reduce tau pathology in AD. Changes in NfL concentration by HMTM indicate a direct impact on disease pathology.

“NfL is a well-studied biomarker with wide applicability to different neurological disorders, including AD,” said Henrik Zetterberg, Professor of Neurochemistry, UCL Queen Square Institute of Neurology. “Clinical practice has been waiting decades to uncover meaningful advancements to address unmet needs of people with AD. These new results further support the importance of NfL as an AD biomarker both for diagnosis and measurement of treatment effect.”

“The NfL results demonstrate that a drug targeting tau pathology reduces the neurodegeneration that underlies clinical decline in AD,” said Claude Wischik, Executive Chairman, TauRx. “They bring us a step closer to offering an effective new treatment option for people with AD. Because it is taken as a tablet and has a strong safety profile, HMTM would be readily accessible to people needing a disease modifying treatment.”

TauRx will submit the HMTM results from LUCIDITY and earlier trials for regulatory approval in the US, UK and other territories.

For additional information, visit: https://taurx.com/ or https://aaic.alz.org/program/scientific-sessions.asp.

THE LUCIDITY TRIAL

LUCIDITY comprised a 12-month double-blind controlled Phase 3 clinical trial followed by a 12-month period in which all participants received HMTM at 16 mg/day. The trial investigated change in various clinical and biomarker outcomes comparing HMTM 16 mg/day with methylthioninium chloride (MTC) given 4 mg twice weekly as a control over the first 12 months. NfL was the principal blood biomarker endpoint in this study. The LUCIDITY trial is now complete and TauRx is preparing publications to report both the NfL data and the full 24-month data.

TAU PATHOLOGY IN AD

Age-related factors lead to misfolding and aggregation of tau proteins, and the subsequent formation of tau tangles in AD. Tau aggregation begins many years before symptoms of dementia appear. Tau aggregation pathology correlates with the clinical decline (loss of memory and ability to care for oneself) commonly seen in people with AD, establishing it as an important target for treatment. HMTM works by inhibiting pathological aggregation of tau protein.

ABOUT TAURX PHARMACEUTICALS LTD

TauRx was founded in 2002 in Singapore, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer’s and other neurodegenerative diseases due to protein aggregation pathology.

Alzheimer’s disease is a leading cause of disability and death throughout the world and is one of the most important public health issues that need to be addressed globally. TauRx will contribute to addressing this unmet need with data from LUCIDITY and pursuit of regulatory approvals in line with its overall plans to make HMTM available to patients and pursue clinical development in other related neurodegenerative diseases. https://www.taurx.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rebecca Andersen
r.andersen@taurx.com
+44 (0)7979 082304

UK
Danielle Thomson
Danielle.thomson@weareaspect.com

US
Uncapped
TauRx@uncappedcommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alipay Supports Over 100 Million Digital Torchbearers to Join the First-Ever Digital Cauldron Lighting for Asian Games24.9.2023 16:17:00 EEST | Press release

The Hangzhou Asian Games has begun with the evening opening ceremony on September 23. The opening ceremony combined Chinese traditions, culture and digital innovations at the Hangzhou Olympic Sports Center Stadium for a spectacular kickoff event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230924810542/en/ Digital torchbearers joining to light the cauldron for the Hangzhou Asian Games (Photo: Business Wire) As the Official Prestige Partner and technology provider of Hangzhou Asian Games, Alipay has supported over 100 million digital torchbearers to join the first-ever digital cauldron lighting in Asian Games history during the ceremony. These digital torchbearers were combined as one digital torchbearer avatar to light the cauldron together with swimming Olympic champion Wang Shun. The Asian Games Digital Torchbearer Online Relay campaign was launched on June 15, 2023, the 100-day countdown to the Games. Participants can

Unitedprint.com collaborates with Pexels.com24.9.2023 11:00:00 EEST | Press release

The e-commerce technology company Unitedprint.com has announced several exciting innovations for its brands Easyprint.com and print24.com. On top of the launch of interactive 2D and 3D product preview visualisations, the company is expanding its offering through a partnership with Pexels.com, a Canva.com company, and is also making more than 12 million premium design templates available to its users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230920567824/en/ Easyprint's FreeDesign tool offers over 3 million royalty-free stock photos and 12 million free design templates (Photo: Business Wire) Cooperation with Pexels.com In close collaboration with Pexels, a subsidiary of Canva.com, Easyprint is expanding its offering to include 3 million royalty-free stock images that users can access free of charge and without restriction for their individual projects. “This partnership will allow our customers to take their creativity

SLB Announces Third-Quarter 2023 Results Conference Call22.9.2023 20:00:00 EEST | Press release

SLB (NYSE:SLB) will hold a conference call on October 20, 2023 to discuss the results for the third quarter ending September 30, 2023. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 8858313. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 20, 2023, and can be accessed by dialing +1 (866) 207-1041 within North America or +1 (402) 970-0847 outsid

Energy Dome's CO2 Battery™ to Revolutionize U.S. Energy Landscape With First Installation Slated for 202622.9.2023 18:45:00 EEST | Press release

A groundbreaking development in sustainable energy storage is on the horizon for Columbia County, Wisconsin, U.S., spearheaded by Alliant Energy in collaboration with Energy Dome and other key stakeholders. Alliant Energy has just announced its selection to receive a federal grant of up to approximately $30 million from the U.S. Department of Energy's Office of Clean Energy Demonstrations (OCED) for the pioneering Columbia Energy Storage Project, a proposed 200-megawatt hour energy storage system, based on Energy Dome’s signature technology: the CO2 Battery™. This visionary battery system, aptly named the “Columbia Energy Storage Project”, is poised to be a trailblazer in the United States, marking a pivotal stride towards a more sustainable, reliable, and cost-effective energy future. Claudio Spadacini, CEO of Energy Dome, declared: “I’m honored to be part of this remarkable journey alongside Alliant Energy. The Columbia Energy Storage Project marks the genesis of a new era, where the

Settlement Administrator Angeion Group Announces Proposed Settlement In U.S. Dollar LIBOR-Based Instrument Class Action22.9.2023 16:00:00 EEST | Press release

There are lawsuits impacting individuals and institutions that entered into over-the-counter financial derivative and non-derivative instruments directly with 17 banks and that received payments tied to U.S. Dollar LIBOR. A Settlement totaling $101 million has been reached with Coöperatieve Rabobank U.A. (“Rabobank”), Lloyds Banking Group plc, Lloyds Bank plc, HBOS plc, and Bank of Scotland plc (together, “Lloyds”), Royal Bank of Canada (“RBC”), and Portigon AG and Westdeutsche Immobilien Servicing AG (together “Portigon”). Earlier settlements totaling $680 million were reached with Barclays, Citibank, Deutsche Bank, HSBC, MUFG, Norinchukin, and SocGen bringing the total settlement amount to $781 million. The remaining Non-Settling Defendants include Bank of America, Credit Suisse, JPMorgan Chase, Royal Bank of Scotland, and UBS. What does the Settlement provide? The Settlement will create a Settlement Fund totaling $101 million that will be used to pay eligible Class Members who submi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom